Harvard Apparatus Regenerative Technology, Inc. (HRGN) — SEC Filings
Harvard Apparatus Regenerative Technology, Inc. (HRGN) — 22 SEC filings. Latest: 10-Q (Nov 7, 2025). Includes 9 8-K, 6 10-Q, 2 DEF 14A.
View Harvard Apparatus Regenerative Technology, Inc. on SEC EDGAR
Overview
Harvard Apparatus Regenerative Technology, Inc. (HRGN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 7, 2025: Harvard Apparatus Regenerative Technology, Inc. (HRGN) reported a net loss of $1.7 million for the three months ended September 30, 2025, an improvement from a net loss of $1.86 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $5.182 million, down fr
Sentiment Summary
Across 22 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 19 neutral. The dominant filing sentiment for Harvard Apparatus Regenerative Technology, Inc. is neutral.
Filing Type Overview
Harvard Apparatus Regenerative Technology, Inc. (HRGN) has filed 6 10-Q, 9 8-K, 2 DEF 14A, 2 10-K, 1 SC 13D, 1 SC 13D/A, 1 SC 13G/A with the SEC between Feb 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (22)
Risk Profile
Risk Assessment: Of HRGN's 19 recent filings, 2 were flagged as high-risk, 11 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $485K |
| Net Income | -$5.182M |
| EPS | -$0.32 |
| Debt-to-Equity | 0.64 |
| Cash Position | $1.319M |
| Operating Margin | -1075.7% |
| Total Assets | $2.546M |
| Total Debt | $0.992M |
Key Executives
- Mao Zhang
- Dr. David E. Pearlman
- Ms. Jennifer L. McNeely
- Josef Volman, Esq.
Industry Context
Harvard Apparatus Regenerative Technology operates in the regenerative medicine and life sciences research sector. This industry is characterized by high R&D investment, long development cycles, and significant regulatory hurdles. Key trends include advancements in cell therapy, tissue engineering, and personalized medicine. The competitive landscape includes established players and numerous startups, often requiring substantial capital to bring innovations to market.
Top Tags
10-Q (5) · material-definitive-agreement (3) · corporate-governance (3) · financials (3) · Biotechnology (2) · Regenerative Medicine (2) · SEC Filing (2) · equity-sale (2) · 10-K (2) · material-agreement (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and cash equivalents | $1.3M | As of September 30, 2025, down from $2.486M at Dec 31, 2024, indicating rapid cash burn. |
| Accumulated deficit | $104.9M | As of September 30, 2025, highlighting significant historical losses. |
| Net loss (Q3 2025) | $1.7M | For the three months ended September 30, 2025, an improvement from $1.86M in Q3 2024. |
| Net loss (YTD 2025) | $5.182M | For the nine months ended September 30, 2025, an improvement from $6.388M in YTD 2024. |
| Product revenue (Q3 2025) | $123K | For the three months ended September 30, 2025, up from $59K in Q3 2024. |
| Product revenue (YTD 2025) | $485K | For the nine months ended September 30, 2025, up from $172K in YTD 2024. |
| Common shares outstanding | 17,168,979 | As of November 3, 2025, indicating potential for further dilution. |
| Net cash used in operating activities (YTD 2025) | $3.164M | For the nine months ended September 30, 2025, demonstrating ongoing cash burn. |
| Proceeds from issuance of common stock (YTD 2025) | $2.0M | For the nine months ended September 30, 2025, indicating recent capital raise. |
| Revenue | $0 | for the three and six months ended June 30, 2025, indicating no commercial sales. |
| Common Stock Shares Outstanding | 15,918,979 | as of June 30, 2025, reflecting the current equity structure. |
| Authorized Common Stock Shares | 60,000,000 | indicating the maximum shares the company can issue. |
| SEC File Number | 001-35853 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 45-5210462 | Company's tax identification number. |
| Total Assets | $15.9M | As of March 31, 2025 |
Frequently Asked Questions
What are the latest SEC filings for Harvard Apparatus Regenerative Technology, Inc. (HRGN)?
Harvard Apparatus Regenerative Technology, Inc. has 22 recent SEC filings from Feb 2024 to Nov 2025, including 9 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of HRGN filings?
Across 22 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 19 neutral. The dominant sentiment is neutral.
Where can I find Harvard Apparatus Regenerative Technology, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Harvard Apparatus Regenerative Technology, Inc. (HRGN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Harvard Apparatus Regenerative Technology, Inc.?
Key financial highlights from Harvard Apparatus Regenerative Technology, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for HRGN?
The investment thesis for HRGN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Harvard Apparatus Regenerative Technology, Inc.?
Key executives identified across Harvard Apparatus Regenerative Technology, Inc.'s filings include Mao Zhang, Dr. David E. Pearlman, Ms. Jennifer L. McNeely, Josef Volman, Esq..
What are the main risk factors for Harvard Apparatus Regenerative Technology, Inc. stock?
Of HRGN's 19 assessed filings, 2 were flagged high-risk, 11 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Harvard Apparatus Regenerative Technology, Inc.?
Forward guidance and predictions for Harvard Apparatus Regenerative Technology, Inc. are extracted from SEC filings as they are enriched.